Published in Blood Cells on January 01, 1990
Absence of ligands bound to glycoprotein IIB-IIIA on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest (1994) 0.96
Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol (2001) 0.83
Reduced platelet hyper-reactivity and platelet-leukocyte aggregation after periodontal therapy. Thromb J (2017) 0.75
Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med (1996) 3.30
Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature (1979) 3.06
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood (2000) 2.12
Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol (1990) 2.00
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood (1998) 1.88
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood (1999) 1.62
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis (1989) 1.57
Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation (1999) 1.54
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Concordance of phenprocoumon dosage in married couples. BMJ (1997) 1.51
Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation (2000) 1.45
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med (1983) 1.44
[Withdrawing the use of acetylsalicyclic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd (2003) 1.42
How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis (2001) 1.41
Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest (1985) 1.40
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase]. Ned Tijdschr Geneeskd (1990) 1.39
Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood (1994) 1.39
The role of collagen in thrombosis and hemostasis. J Thromb Haemost (2004) 1.38
Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol (2000) 1.32
The hemostatic plug. Semin Hematol (1977) 1.31
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med (1981) 1.29
Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation (2003) 1.28
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest (1994) 1.23
Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood (1983) 1.23
A new method to study shape recovery of red blood cells using multiple optical trapping. Biophys J (1995) 1.23
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet (1998) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol (1986) 1.20
Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure (1997) 1.20
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood (1997) 1.17
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Structural studies on the O-linked carbohydrate chains of human platelet glycocalicin. Eur J Biochem (1984) 1.14
Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost (1988) 1.14
Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood (1997) 1.12
Subendothelial proteins and platelet adhesion. von Willebrand factor and fibronectin, not thrombospondin, are involved in platelet adhesion to extracellular matrix of human vascular endothelial cells. Arteriosclerosis (1986) 1.12
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from alpha-granules to the cell surface. J Cell Biol (1997) 1.12
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Hemostasis in menstrual endometrium: a review. Obstet Gynecol Surv (1982) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem (1987) 1.10
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Von Willebrand factor in the vessel wall mediates platelet adherence. Blood (1985) 1.09
Thrombosis and hemostasis in renal disease. Kidney Int (1994) 1.09
Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation (1992) 1.07
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood (1991) 1.07
Kinetics of intravenously administered heparin in normal humans. Blood (1982) 1.06
Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem (2000) 1.06
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Adenine nucleotide metabolism of blood platelets. 8. Transport of adenine into human platelets. Biochim Biophys Acta (1973) 1.04
A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost (1996) 1.04
Fibronectin in artery subendothelium is important for platelet adhesion. Blood (1985) 1.04
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
Red blood cell deformability influences platelets--vessel wall interaction in flowing blood. Blood (1984) 1.02
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Immunocytochemical localization of albumin and factor XIII in thin cryo sections of human blood platelets. Thromb Haemost (1984) 1.01
Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood (1984) 1.01
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest (1988) 1.01
Platelet adherence to subendothelium of human arteries in pulsatile and steady flow. Thromb Res (1981) 0.99
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 0.98
Neutrophil adhesion to fibrinogen and fibrin under flow conditions is diminished by activation and L-selectin shedding. Blood (1997) 0.97
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation (1993) 0.97
Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation (2001) 0.97
Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest (1978) 0.97
Responses of platelets to strains of streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen-unresponsive patients. Thromb Haemost (1987) 0.97
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost (2000) 0.96
Absence of ligands bound to glycoprotein IIB-IIIA on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest (1994) 0.96
Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis (1990) 0.95
Factor VIII and von Willebrand factor. Thromb Haemost (1998) 0.95
Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol (1997) 0.95
Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood (1987) 0.94